Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43861   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-000810-31
    Sponsor's Protocol Code Number:na
    National Competent Authority:Netherlands - Competent Authority
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2016-03-14
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedNetherlands - Competent Authority
    A.2EudraCT number2016-000810-31
    A.3Full title of the trial
    Impact of L-Carnitine infusion on Lipid induced Insulin resistance
    Effect van L-Carnitine infusie op lipiden geïnduceerde insuline resistentie
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Effect of L-Carnitine on insuline sensitivity
    Effect van L-Carnitine infusie op insuline gevoeligheid
    A.3.2Name or abbreviated title of the trial where available
    Carnitine infusion and Insulin resistance
    Carnitine infusie en insuline resistentie
    A.4.1Sponsor's protocol code numberna
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorMaastricht University
    B.1.3.4CountryNetherlands
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportnutrim
    B.4.2CountryNetherlands
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationUniversiteit Maastricht
    B.5.2Functional name of contact pointnutrim
    B.5.3 Address:
    B.5.3.1Street AddressUniversiteitssingel 40
    B.5.3.2Town/ cityMaastricht
    B.5.3.3Post code6229ER
    B.5.3.4CountryNetherlands
    B.5.4Telephone number0031433881476
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Carnitor
    D.2.1.1.2Name of the Marketing Authorisation holderSigma-Tau Pharmaceuticals
    D.2.1.2Country which granted the Marketing AuthorisationNetherlands
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCarnitor
    D.3.4Pharmaceutical form Infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Glucose tolerance
    Glucose tolerantie
    E.1.1.1Medical condition in easily understood language
    Glucose tolerance: the switch between fatoxidation in the fasted state and glucose oxidation in the fed state.
    Glucose tolerantie : het kunnen wisselen tussen vetverbranding in de gevaste staat en suikerverbranding in de gevoede staat.
    E.1.1.2Therapeutic area Diseases [C] - Nutritional and Metabolic Diseases [C18]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objectives are to investigate whether L-carnitine infusion may rescue lipid-induced insulin resistance and whether L-carnitine infusion is improving metabolic flexibility in the state of lipid-induced insulin resistance.
    Onderzoeken of infusie van L-carnitine lipiden geïnduceerde insuline resistentie kan tegengaan/voorkomen.
    E.2.2Secondary objectives of the trial
    a secondary objective is to examine the molecular pathways of carnitine and acetylcarnitine, responsible for muscle insulin sensitivity.
    onderzoeken welke moleculaire pathways van carnitine and acetylcarnitine betrokken zijn bij insuline gevoeligheid
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    • Caucasian
    • Healthy (as determined by responsible physician based on a medical questionnaire)
    • Male
    • Age: 18-40 years
    • Normal BMI: 18-25 kg/m2
    • Stable dietary habits
    • No use of medication interfering with investigated study parameters (as determined by responsible physician)
    Caucasian
    • Gezond
    • Man
    • Leeftijd: 18-40 jaar
    • Normaal BMI: 18-25 kg/m2
    • Stabiele voedingsgewoonten
    • Geen medicijngebruik dat interfereert met de studieparameters
    E.4Principal exclusion criteria
    • Female
    • Haemoglobin levels < 7.8 mmol/L
    • Uncontrolled hypertension
    • Use of anticoagulants
    • Engagement in exercise > 3 hours a week
    • Being vegetarian or vegan (because of altered whole body carnitine status)
    • Smoking
    • Alcohol and/or drug abuse
    • Unstable body weight (weight gain or loss > 5kg in the last 3 months)
    • Significant food allergies/intolerances (seriously hampering study meals)
    • Participation in another biomedical study within 1 month before the first study visit, which would possibly hamper our study results
    • Medication use known to hamper subject’s safety during the study procedures
    • Medication use known to interfere with investigated study parameters
    • Subjects with contra-indications for MRI
    • Subjects who intend to donate blood during the intervention or subjects who have donated blood less than three months before the start of the study
    • Subjects who do not want to be informed about unexpected medical findings
    • Subjects who do not want that their treating physician is informed
    • Vrouw
    • Haemoglobine levels < 7.8 mmol/L
    • Ongecontroleerde hypertensie
    • Gebruik van bloedverdunners
    • Sporten > 3 uur per week
    • Vegetarisch of veganistisch
    • Roken
    • Alcohol en/of drugsmisbruik
    • Onstabiel lichaamsgewicht (gewichtstoename of -afname > 5kg in de afgelopen 3 maanden)
    • Voedingsallergie of intolerantie
    • Deelname in een andere biomedische studie binnen 1 maand voor aanvang aan de huidige studie.
    • Medicijngebruik dat de veiligheid van de proefpersoon kan schaden tijdens de studie
    • Medicatie gebruik dat interfereert met de onderzochte parameters in de studie
    • Contra-indicaties voor de MRI
    • Proefpersonen die bloed willen doneren tijdens de studie of binnen 3 maanden voor aanvang van de studie
    • Proefpersonen die niet geïnformeerd willen worden over toevalsbevindingen
    • Proefpersonen die niet willen dat de huisarts geïnformeerd wordt over deelname aan de studie
    E.5 End points
    E.5.1Primary end point(s)
    - Whole body insulin sensitivity measured as GIR in µmol/kg/min during the stable period of the insulin phase of the clamp.
    - Peripheral insulin sensitivity measured as Rd in µmol/kg/min.
    - Metabolic flexibility (delta RER between basal and insulin stimulated state).
    Insuline gevoeligheid van het hele lichaam weergegeven als GIR in µmol/kg/min tijdens de stabiele fase van de insuline tijdens de clamp.

    Perifere insuline gevoeligheid als Rd in µmol/kg/min

    Metabole flexibiliteit ( delta RER tussen basaal en insuline)
    E.5.1.1Timepoint(s) of evaluation of this end point
    after 3 subjects
    na 3 proefpersonen
    E.5.2Secondary end point(s)
    Maximal acetylcarnitine concentrations after exercise (measured using the 1H-MRS cycling measurement)
    -Metabolites in the blood before and during insulin stimulation (i.e. glucose, free fatty acids, triglycerides, cholesterol, insulin)
    - CrAT activity (measured in muscle biopsies)
    - Acylcarntine profiles (measured in muscle biopsies)
    - Lipid and lipid intermediates (measured in muscle biopsies)
    Maximale acetylcarnitine concentratie na inspanning (1H-MRS)

    Metabolieten in het bloed tijdens de insuline stimulatie (glucose, FFA, triglyceriden, cholesterol, insuline)

    CraT activiteit (spierbiopt)

    Acetylcarnitine profiel (spierbiopt)

    Lipiden en lipiden intermediaren (spierbiopt)
    E.5.2.1Timepoint(s) of evaluation of this end point
    na 10 proefpersonen
    na 10 proefpersonen
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis Yes
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety No
    E.6.5Efficacy No
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind Yes
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over Yes
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    FYSIOLOGISCH ZOUT
    SALINE
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months8
    E.8.9.1In the Member State concerned days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 18
    F.1.3Elderly (>=65 years) No
    F.1.3.1Number of subjects for this age range: 0
    F.2 Gender
    F.2.1Female No
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers Yes
    F.3.2Patients No
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state18
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-03-14
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-07-08
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 26 06:57:18 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA